Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John Ross Clark, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Shi CR, Shaughnessy M, Sehgal K, Clark JR, Reynolds KL, Toyohara J, Chen ST. Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction. Int J Dermatol. 2023 Jan 11. PMID: 36628976.
    Citations:    Fields:    
  2. Zafar A, Drobni ZD, Lei M, Gongora CA, Quinaglia T, Lou UY, Mosarla R, Murphy SP, Jones-O'Connor M, Mahmood A, Hartmann S, Gilman HK, Weekes CD, Nipp R, Clark JR, Clark JW, Blaszkowsky LS, Tavares E, Neilan TG. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS One. 2022; 17(4):e0265767. PMID: 35390017; PMCID: PMC8989300.
    Citations: 2     Fields:    Translation:Humans
  3. Siravegna G, O'Boyle CJ, Varmeh S, Queenan N, Michel A, Stein J, Thierauf J, Sadow PM, Faquin WC, Perry SK, Bard AZ, Wang W, Deschler DG, Emerick KS, Varvares MA, Park JC, Clark JR, Chan AW, Andreu Arasa VC, Sakai O, Lennerz J, Corcoran RB, Wirth LJ, Lin DT, Iafrate AJ, Richmon JD, Faden DL. Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. Clin Cancer Res. 2022 02 15; 28(4):719-727. PMID: 34857594; PMCID: PMC8866203.
    Citations: 3     Fields:    Translation:HumansCells
  4. O'Boyle CJ, Siravegna G, Varmeh S, Queenan N, Michel A, Pang KCS, Stein J, Thierauf JC, Sadow PM, Faquin WC, Wang W, Deschler DG, Emerick KS, Varvares MA, Park JC, Clark JR, Chan AW, Busse PM, Corcoran RB, Wirth LJ, Lin DT, Iafrate AJ, Richmon JD, Faden DL. Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer. Cancer. 2022 06 01; 128(11):2193-2204. PMID: 35139236; PMCID: PMC10032347.
    Citations: 7     Fields:    Translation:HumansCells
  5. Oh J, Carlson JCT, Landeros C, Lee H, Ferguson S, Faquin WC, Clark JR, Pittet MJ, Pai SI, Weissleder R. Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling. Clin Cancer Res. 2021 09 01; 27(17):4781-4793. PMID: 34233961; PMCID: PMC8416923.
    Citations: 8     Fields:    Translation:HumansAnimals
  6. Hanna GJ, ONeill A, Cutler JM, Flynn M, Vijaykumar T, Clark JR, Wirth LJ, Lorch JH, Park JC, Mito JK, Lohr JG, Kaufman J, Burr NS, Zon LI, Haddad RI. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol. 2021 08; 119:105366. PMID: 34091189.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  7. Zafar A, Drobni ZD, Mosarla R, Alvi RM, Lei M, Lou UY, Raghu VK, Murphy SP, Jones-O'Connor M, Hartmann S, Gilman HK, Weekes CD, Clark JR, Clark J, Blaszkowsky L, Tavares E, Neilan TG. The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. JACC CardioOncol. 2021 Mar; 3(1):101-109. PMID: 33817666; PMCID: PMC8018593.
    Citations: 13     
  8. Park JC, Durbeck J, Clark JR. Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma. Mol Clin Oncol. 2020 Dec; 13(6):87. PMID: 33194194; PMCID: PMC7657085.
    Citations: 4     
  9. Park JC, Durbeck J, Clark JR, Faden DL. Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes. Oral Oncol. 2020 12; 111:105024. PMID: 33065374.
    Citations: 1     Fields:    Translation:HumansCells
  10. Koenigs MB, Lefranc-Torres A, Bonilla-Velez J, Patel KB, Hayes DN, Glomski K, Busse PM, Chan AW, Clark JR, Deschler DG, Emerick KS, Hammon RJ, Wirth LJ, Lin DT, Mroz EA, Faquin WC, Rocco JW. Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy. J Natl Cancer Inst. 2019 09 01; 111(9):933-942. PMID: 30715409.
    Citations: 17     Fields:    Translation:HumansCells
  11. El-Jawahri A, Quinn K, Arcikowski L, Chan G, Viscosi E, Doherty C, Clark JR, Wirth LJ, Temel JS. Patient reported outcomes (PROs) in patients with human papilloma virus (HPV) positive versus negative head and neck cancer (HNC). J Clin Oncol. 2016 Oct 09; 34(26_suppl):87. PMID: 28156440.
    Citations:    
  12. El-Jawahri A, Quinn K, Arcikowski L, Chan G, Viscosi E, Doherty C, Clark JR, Temel JS, Wirth LJ. A two-group study to evaluate the impact of an educational handbook in the care of patients with head and neck cancer (HNC). J Clin Oncol. 2016 Oct 09; 34(26_suppl):228. PMID: 28156655.
    Citations:    
  13. McBride SM, Rothenberg SM, Faquin WC, Chan AW, Clark JR, Ellisen LW, Wirth LJ. Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma. Head Neck. 2014 Aug; 36(8):1181-8. PMID: 23852799.
    Citations: 12     Fields:    Translation:Humans
  14. McBride SM, Busse PM, Clark JR, Wirth LJ, Ancukiewicz M, Chan AW. Long-term survival after distant metastasis in patients with oropharyngeal cancer. Oral Oncol. 2014 Mar; 50(3):208-12. PMID: 24387975.
    Citations: 10     Fields:    Translation:Humans
  15. Emerick KS, Leavitt ER, Michaelson JS, Diephuis B, Clark JR, Deschler DG. Initial clinical findings of a mathematical model to predict survival of head and neck cancer. Otolaryngol Head Neck Surg. 2013 Oct; 149(4):572-8. PMID: 23797612.
    Citations: 11     Fields:    Translation:Humans
  16. Fradley MG, Barrett CD, Clark JR, Francis SA. Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity. Tex Heart Inst J. 2013; 40(4):472-6. PMID: 24082383.
    Citations: 4     Fields:    Translation:Humans
  17. Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, Clark JR, Wein RO, Grillone GA, Houseman EA, Halec G, Waterboer T, Pawlita M, Krane JF, Kelsey KT. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 2012 Oct 01; 72(19):5004-13. PMID: 22991304.
    Citations: 58     Fields:    Translation:HumansCells
  18. Chang G, Chang T, Pan T, Clark JW, Mawlawi OR. Determination of internal target volume from a single positron emission tomography/computed tomography scan in lung cancer. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):459-66. PMID: 22197228.
    Citations: 3     Fields:    Translation:Humans
  19. Nichols AC, Kneuertz PJ, Deschler DG, Lin DT, Emerick KS, Clark JR, Busse PW, Rocco JW. Surgical salvage of the oropharynx after failure of organ-sparing therapy. Head Neck. 2011 Apr; 33(4):516-24. PMID: 20652974.
    Citations: 12     Fields:    Translation:Humans
  20. Nichols AC, Finkelstein DM, Faquin WC, Westra WH, Mroz EA, Kneuertz P, Begum S, Michaud WA, Busse PM, Clark JR, Rocco JW. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res. 2010 Apr 01; 16(7):2138-46. PMID: 20233885.
    Citations: 22     Fields:    Translation:HumansCells
  21. Poage GM, Christensen BC, Houseman EA, McClean MD, Wiencke JK, Posner MR, Clark JR, Nelson HH, Marsit CJ, Kelsey KT. Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted. PLoS One. 2010 Mar 11; 5(3):e9651. PMID: 20300172.
    Citations: 21     Fields:    Translation:HumansCells
  22. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW, Rocco JW. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2009 Mar 01; 15(5):1645-54. PMID: 19240170.
    Citations: 37     Fields:    Translation:HumansCells
  23. Nichols AC, Faquin WC, Westra WH, Mroz EA, Begum S, Clark JR, Rocco JW. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009 Feb; 140(2):228-34. PMID: 19201294.
    Citations: 35     Fields:    Translation:HumansCells
  24. Busse PM, Clark JR, Muse VV, Liu V. Case records of the Massachusetts General Hospital. Case 19-2008. A 63-year-old HIV-positive man with cutaneous Merkel-cell carcinoma. N Engl J Med. 2008 Jun 19; 358(25):2717-23. PMID: 18565865.
    Citations: 7     Fields:    Translation:Humans
  25. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar; 18(3):317-23. PMID: 17985985.
    Citations: 73     Fields:    Translation:HumansCTClinical Trials
  26. Furniss CJ, McClean MD, Smith JF, Bryan J, Nelson HH, Peters ES, Posner MR, Clark JR, Eisen EA, Kelsey KT. Human papillomavirus 16 and head and neck squamous cell carcinoma. International Journal of Cancer. 2007; 120(11):2386-92.
  27. Furniss CS, McClean MD, Smith JF, Bryan J, Nelson HH, Peters ES, Posner MR, Clark JR, Eisen EA, Kelsey KT. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer. 2007 Jun 01; 120(11):2386-92. PMID: 17315185.
    Citations: 54     Fields:    Translation:HumansCells
  28. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8. PMID: 16299242.
    Citations: 48     Fields:    Translation:HumansCells
  29. Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer. 2005 Oct 01; 104(7):1418-27. PMID: 16116597.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  30. Karakoyun-Celik O, Norris CM, Tishler R, Mahadevan A, Clark JR, Goldberg S, Devlin P, Busse PM. Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base. Head Neck. 2005 May; 27(5):353-61. PMID: 15726587.
    Citations: 3     Fields:    Translation:Humans
  31. Devlin PM, Kazakin J, Adak S, Li Y, Norris CM, Tishler RB, Clark JR, Busse PM, Posner MR. Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up. Am J Clin Oncol. 2004 Aug; 27(4):369-75. PMID: 15289730.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  32. Clark JR, Trautwein LM, Campbell JR. An unusual cause of refusal to walk. Semin Pediatr Infect Dis. 2003 Oct; 14(4):257, 323-5. PMID: 14724790.
    Citations: 1     Fields:    Translation:HumansCells
  33. Penson RT, Fergus LA, Haston RJ, Clark JR, Demotses A, O'Connell JJ, Chabner BA, Lynch TJ. The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless. Oncologist. 2003; 8(5):488-95. PMID: 14530502.
    Citations: 3     Fields:    Translation:Humans
  34. Devlin p, Kazakin J, Adak S, Li Y, norris C, Clark J, Tishler R, Busse P, Posner M. Phase II trial of PFL-induction therapy for HNSCC: 10 year follow up. ASCO. 2002.
  35. Boyd-Sirard C, Thurer R, Bergman M, Berman S, LoCicero J, Huberman M, Boiselle P, Oldenburg N, Coute D, Krikorian J, Clark J, Karp D. A phase II study of weekly taxol and carboplatinum with concomitant full dose radiotherapy: a novel pre-operative regimen for bulky stage III non small cell lung cancer. ASCO. 2002.
  36. Posner MR, Johnston PG, Tishler RB, Andersen J, Florentino M, Busse PM, Cavicini LA, Colevas AD, Clark JR, Norris CM. The prognostic value of thymidylate synthetase and p53 expression in patients treated with induction chemotherapy for squamous cell carcinoma of the head and neck. The Oncologist. 1998; 3:424-431.
  37. Clark JR, Busse PM, Norris CM, Andersen JW, Dreyfuss AI, Rossi RM, Poulin MD, Colevas AD, Tishler R, Costello R, Lucarini D, Thornhill L, Lackey M, Posner MR. Induction Chemotherapy with Cisplatin, 5-Fluorouracil andHigh Dose Leucovorin for Squamous Cell Carcinomas of the Head & Neck: Long Term Results. Journal of Clinical Oncology. 1997; 15:3100-3110.
  38. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996 May; 14(5):1672-8. PMID: 8622087.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  39. Posner M, Dreyfuss A, Clark J, Norris C, Rossi R, Lucarini J, Busse P, Poulin M, Costello R, Thornhill L. Docetaxel for advanced, incurable squamous cell carcinoma of the head and neck. ASCO. 1996.
  40. Schwartz GN, Clark JR. The role of chemotherapy in management of carcinomas of the larynx and hypopharynx. The larynx: a multidisciplinary approach, 2nd edition, Fried M. 1996; 579-610.
  41. Clark J, Busse P, Norris C, Dreyfuss A, Rossi R, Poulin M, Thornhill L, Costello R, Lackey M, Posner M. Long term results of induction chemotherapy with cisplatin, 5-FU and high dose leucovorin for squamous cell carcinoma of the head and neck. ASCO. 1996.
  42. Dreyfuss, A, Posner M, Clark J, Norris C, Rossi R, Poulin M, Busse P, Costello R. Docetaxel: an active drug against squamous cell carcinoma of the head and neck. ASCO. 1995.
  43. Dreyfuss A, Clark J, Norris C, Rossi R, Lucarini J, Busse P, Poulin M, Costello R. Taxotere for advanced incurable squamous cell carcinoma of the head and neck. ASCO. 1994.
  44. Buswell L, Recht A, Clark J, Ravikumar T, Busse P, Coleman C. Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with and without surgery: neurotoxicity, other toxicities and outcome. Int J Rad Oncol Biol Phys. 1994; 29:535-540.
  45. Kelsey KT, Caggana M, Mauch PM, Coleman CN, Clark JR, Liber HL. Mutagenesis after cancer therapy. Environ Health Perspect. 1993 Oct; 101 Suppl 3:177-84. PMID: 8143613; PMCID: PMC1521128.
    Citations:    Fields:    Translation:Humans
  46. Busse P, Clark J. The diagnosis and staging of head and neck cancer. Advances in Oncology. 1993.
  47. Buswell L, Recht A, Clark J, Ravikumar T, Coleman CN. Incidence of peripheral neuropathy in patients treated with etanidazole and cisplatin for esophageal cancer. Presented at the International Chemical Modifiers Meeting, Kyoto Japan. 1993.
  48. Clark J, Dreyfuss A, Busse P, Norris C Jr, Lucarini J, Rossi R, Andersen J, Casey D, Frei E III. Neo-adjuvant infusion cisplatin, 5-fluorouracil and high-dose leucovorin for squamous cell carcinoma of the head and neck: rhigh rates of response and definitive radiotherapy as primary site managemen. Neo-adjuvant Chemotherapy: Proceedings of the Fourth International Congress. 1993.
  49. Busse PM, Clark JR, Beard CJ, Dreyfuss AI, Lucarini J, Rossi R, Casey D, Norris C. Primary site management following induction chemotherapy with cis-platin, 5-fluorouracil and leucovorin. Head and Neck. 1993; 15:413-418.
  50. Norris CM, Busse, PM, Clark JR. Evolving role of surgery after induction chemotherapy and promary site radiation in head and neck cancer. Seminars in Oncology. 1993; 9:3-13.
  51. Norris CM, Busse PM, Clark JR. Evolving role of surgery after induction chemotherapy and primary site radiation in head and neck cancer. Semin Surg Oncol. 1993 Jan-Feb; 9(1):3-13. PMID: 8356382.
    Citations: 1     Fields:    Translation:Humans
  52. Dreyfuss AI, Clark JR, Andersen JW. Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck. Cancer. 1992 Nov 15; 70(10):2499-503. PMID: 1423179.
    Citations: 1     Fields:    Translation:Humans
  53. Clark JR, Dreyfuss AI. The role of salvage chemotherapy in the treament of head and neck cancer. Proceedings of the 3rd International Conference on Head and Neck Cancer, San Francisco, July 26-30. 1992.
  54. Morrison B, Clark J. Induction Chemotherapy. Multimodality Therapy for Head and Neck Cancer, Snow GB, Clark JR. 1992; 95-112.
  55. Lockhart P, Norton J, Clark J. Preradiotherapy dental status of patients with head and neck tumors. Presented at the American Association for Dental Research, Boston, MA. 1992.
  56. Clark JR. Chemotherapy for head and neck cancer: facts, fiction and recent progress. Cancer Update II, Taguchi T. 1992; 41-55.
  57. Lynch TJ, Clark JR, Elias AD, Skarin AT. PFM in patients with advanced NSCLC. Cancer. 1992.
  58. Caggana M, Liber HL, Coleman CN, Mauch P, Clark JR, Kelsey KT. A prospective study of HRPT mutant and mutation frequencies in treated cancer patients. Cancer Epidemiology, Biomarkers and Prevention. 1992; 1:573-580.
  59. Snow G, Clark J. Multimodality Therapy for Head and Neck Cancer. 1992; 1-188.
  60. Dreyfuss AI, Clark JR. Analysis of prognostic factors in squamous cell carcinomas of the head and neck. Hematol Oncol Clin North Am. 1991 Aug; 5(4):701-12. PMID: 1890061.
    Citations: 3     Fields:    Translation:Humans
  61. Clark JR, Dreyfuss AI. The role of cisplatin in treatment regimens for squamous cell carcinoma of the head and neck. Semin Oncol. 1991 Feb; 18(1 Suppl 3):34-48. PMID: 2003226.
    Citations: 3     Fields:    Translation:Humans
  62. Clark J, Dreyfuss A, Norris C Jr, Busse P, Beard C, Lucarini J, Andersen J, Miller D, Casey D, Frei E III. Neo-adjuvant cisplatin, 5-fluorouracil and high-dose leucovorin for advanced head and neck cancer: response, toxicity, survival and comparison with historical controls. Accepted for presentation at the Third International Congress on Neo-Adjuvant Chemotherapy, Paris, France. 1991.
  63. Busse P, Clark J, Norris C Jr, Dreyfuss A, Beard C, Lucarini J, Andersen J, Miller D, Casey D, Frei E III. Regional control after induction chemotherapy for advanced squamous cell carcinoma of the head and neck: a retrospective analysis of 303 patients. Neo-adjuvant Chemotherapy: Proceedings of the Third International Congress. 1991; 41-44.
  64. Busse P, Clark J, Norris C Jr, Dreyfuss A, Beard C, Lucarini J, Andersen J, Miller D, Casey D, Frei E III. Regional control after induction chemotherapy for advanced squamous cell carcinoma of the head and neck: a retrospective analysis of 303 patients. Accepted for presentation at the Third International Congress on Neo-Adjuvant Chemotherapy, Paris, France. 1991.
  65. Busse P, Clark J, Norris C Jr, Dreyfuss A, Beard C, Lucarini J, Andersen J, Casey D, Miller D. Regional control after induction chemotherapy for advanced squamous cell carcinoma of the head and neck: a retrospective analysis of 303 patients. Accepted for presentation the American Society for Therapeutic Radiation Oncologists. 1991.
  66. Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 5. 1991; 11-18.
  67. Clark J, Dreyfuss A, Norris C Jr, Busse P, Beard C, Lucarini J, Andersen J, Miller D, Casey D, Frei E III. Neo-adjuvant cisplatin, 5-fluorouracil and high-dose leucovorin for advanced head and neck cancer: response, toxicity, survival and comparison with historical controls. Neo-adjuvant Chemotherapy: Proceedings of the Third International Congress. 1991; 50-53.
  68. Clark J. Cancer of the head and neck region. Cancer Atlas, Skarin A. 1991; 1.2-1.35.
  69. Clark J, Busse P, Norris C Jr, Dreyfuss A, Beard C, Lucarini J, Andersen J, Miller D, Casey D, Frei E III. Regional control after induction therapy for head and neck cancer: an analysis of 303 patients and a proposal for management of the neck. Accepted for presentation at the American Society for Clinical Oncology, Houston TX. 1991.
  70. Dreyfuss AI, Clark JR, Wright JE, Norris CM, Busse PM, Lucarini JW, Fallon BG, Casey D, Andersen JW, Klein R, et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med. 1990 Feb 01; 112(3):167-72. PMID: 2297193.
    Citations: 11     Fields:    Translation:Humans
  71. Frei E III, Antman K, Clark J. Dose - a critical factor in cancer chemotherapy. Cancer Update: Current Topics in Research. Based on an international educational seminar held in Tokyo, July 15-16, 1989 Tokyo. 1990; 31-46.
  72. Clark J, Dreyfuss A, Norris C Jr, Busse P, Miller D, Lucarini J, Andersen J, Casey D, Frei E III. Continuous infusion cisplatin, 5-FU and high-dose leucovorin (PFL): favorable early results as induction therapy for squamous cell carcinoma of the head and neck (SCCHN). Presented American Society for Clinical Oncology. 1990.
  73. Clark J, Vaughan C, Fitzgerald T, Costello R. Cancer of the head and neck. Cancer manual, 8th Edition, Osteen R. 1990; 145-160.
  74. Clark J, Dreyfuss A, Busse, P, Norris C Jr, Miller D, Lucarini J, Andersen J, Casey D, Frei E III. Cintinuous infusion cisplatin, 5-FU and high-dose leucovorin (PFL): An induction therapy for squamous cell carcinoma of the head and neck (SCCHN) with high rates of complete respoonse and radiotherapy alone as primary site management. Presented 6th International Conference on the Adjuvant Therapy of Cancer, Tuscon, AZ. 1990.
  75. Lockhart PB, Clark JR. Oral complications following neoadjuvant chemotherapy in patients with head and neck cancer. NCI Monogr. 1990; (9):99-101. PMID: 2342598.
    Citations: 2     Fields:    Translation:Humans
  76. Clark J, Dreyfuss A, Busse, P, Norris C Jr, Miller D, Lucarini J, Andersen J, Casey D, Frei E III. Cintinuous infusion cisplatin, 5-FU and high-dose leucovorin (PFL): An induction therapy for squamous cell carcinoma of the head and neck (SCCHN) with high rates of complete response and radiotherapy alone as primary site management. Adjuvant Therapy of Cancer VI. 1990; 71-81.
  77. Herman TS, Jochelson MS, Teicher BA, Scott PJ, Hansen J, Clark JR, Pfeffer MR, Gelwan LE, Molnar-Griffin BJ, Fraser SM, et al. A phase I-II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1273-9. PMID: 2689396.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  78. Clark JR, Frei E. Chemotherapy for head and neck cancer: progress and controversy in the management of patients with M0 disease. Semin Oncol. 1989 Aug; 16(4 Suppl 6):44-57. PMID: 2669137.
    Citations: 3     Fields:    Translation:Humans
  79. Blazer BA, Fried MP, Strome M, Clark JR, Sereno P, Rodliff S, Caminear D. Circulating immune complexes are predictive of responses to chemotherapy in patients with head and cancer. Head and Neck Surgery. 1989; 11:431-436.
  80. Clark JR, Fallon BG, Dreyfuss AI, Andersen J, Norris CM Jr, Chaffey JT, Miller D. Induction chemotherapy for advanced cancer of the head and neck. Head and Neck Cancer, Fee WE, Gorpfert H, Johns ME, Strong EW, Ward PH. 1989; 2:287-295.
  81. Dreyfuss A, Clark J, Fallon B, Miller D, Busse P, Casey D, Costello R, Norris C Jr, Lucarini J, Wright J, Rosowsky A, Frei E III. Continuous infusion cisplatin, 5-FU and high dose leucovorin as induction chemotherapy for squamous cell carcinoma of the head and neck: preliminary results of a Dana-Farber regimen. Proceedings of the Annual meeting of the American Society for Clinical Oncology, San Francisco, CA. 1989.
  82. Strome M, Clark JR, Fried MP, Rodliff S, Blazar BA. The prognostic implications of defining natural killer cell function and T cell subsets in patients with squamous cell carcinoma. Head and Neck Cancer, Fee WE, Gorpfert H, Johns ME, Strong EW, Ward PH. 1989; 2:89-93.
  83. Million RR, Cassisi NJ, Clark JR. Cancer of the head and neck. DeVita VT, Hellman S, Rosenberg SA, Cancer: Principles and practice of oncology, 3rd edition. 1989; 488-590.
  84. Wright JE, Clark J, Dreyfuss A, Trites D, Klein R, Rosowsky A, Frei E III. Pharmocology of leucovorin given in combination with cisplatin and fluorouracil for head and neck cancinoma. Presented at the Annual meeting of the American Association for Cancer Research, San Francisco, CA. 1989.
  85. Clark JR, Fallon BG, Dreyfuss AI, Norris CM, Anderson JW, Ervin TJ, Anderson RF, Chaffey JT, Miller D, Frei E. Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer. Semin Oncol. 1988 Jun; 15(3 Suppl 3):35-44. PMID: 3393916.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  86. Herman TS, Teicher BA, Jochelson M, Clark J, Svensson G, Coleman CN. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia. 1988 Mar-Apr; 4(2):143-58. PMID: 3283266.
    Citations: 18     Fields:    Translation:HumansAnimalsCTClinical Trials
  87. Clark J, Fallon B, Dreyfuss A, Anderson J, Norris C Jr, Anderson R, Miller D, Frei E III. Infusion cisplatin and 5-fluorouracil with methotrexate/leucovorin for advanced, previously untreated squamous cell carcinoma of the head and neck. Presentated at the Annual meeting of the American Society for Clinical Oncology, New Orleans, LA. 1988.
  88. Frei E III, Clark JR, Miller D, Bernal SB, Teicher B. Neo adjuvant chemotherapy for head and neck cancer; basic and strategic considerations. Presented at the Second International Congress on Neo-Adjuvant Chemotherapy, Paris, France. 1988.
  89. Weichselbaum RR, Beckett M, Panje WR, Goldman M, Tybor AG, Moran WJ, Vokes E, Ahmed-Swan S, Chen P, Ervin TJ, Clark J. Radioresistant human squamous cell carcinoma cells may account for radiotherapy failure in head and neck cancer. Head and Neck Oncology Research. 1988; 463-466.
  90. Dreyfuss A, Clark J, Anderson J, Fallon B, Costello R, Miller D. Evaluation of tumor markers in patients with squamous cell carcinoma of the head and neck. Presented at the Annual meeting of the American Society for Clinical Oncology, New Orleans, LA. 1988.
  91. Clark JR, Fallon BG. The role of chemotherapy in the management of laryngeal and hypopharyngeal carcinoma. The larynx: a multidisciplinary approach, Fried M. 1988; 591-601.
  92. Fallon BG, Clark J, Norris C Jr, Balogh K, Domanowski G, Andersen J, Dreyfuss A, Anderson R, Chaffey J, Miller D. Induction chemotherapy in advanced stage III/IV squamous cell carcinoma of the head and neck : An analysis of clinical and histopathologic correlates after a complete response to chemotherapy. Head and Neck Oncology Research. 1988; 281-286.
  93. Frei E III, Clark JR, Miller D, Bernal SB, Teicher B. Neo adjuvant chemotherapy for head and neck cancer; basic and strategic considerations. Presented at the Second International Congress on Neo-Adjuvant Chemotherapy, Paris, France. 1988.
  94. Blazer BA, Strome M, Clark JR, Sereno P, Rodliff S, Caminear D, Fried MP. Circulating immune complexes are predictive of responses to chemotherapy in patients with head and cancer. Presented at the Second International Conference on Head and Neck Cancer, Boston MA. 1988.
  95. Frei E III, Clark JR, Miller D. Neoadjuvant chemotherapy for head and neck cancer: Problems and prospects. Neo-Adjuvant Chemotherapy: Second International Congress, Jacquillat C, Weil M, Khayat D. 1988; 169:259-273.
  96. Strome M, Clark JR, Fried MP, Rodliff S, Blazar BA. T-cell subsets and natural killer cell function with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1987 Oct; 113(10):1090-3. PMID: 3497652.
    Citations: 2     Fields:    Translation:HumansCells
  97. Frei E III, Clark JR, Miller D. The concept of neoadjuvant chemotherapy. Adjuvant Therapy of Cancer V, Salmon SE. 1987; 67-75.
  98. Clark JR, Norris C Jr, Dreyfuss A, Fallon B, Balogh K, Anderson R, Chaffey J, Miller D. Nasopharyngeal carcinoma (NPC): The Dana-Farber Cancer Institute experience with 24 patients treated with induction chemotherapy (CT) and radiotherapy (RT). Presented at the American Laryngologic Society Meeting. 1987.
  99. Clark JR. Multidisciplinary treatment of head and neck cancer with chemotherapy: Update. Presented at the annual meeting of the American Society of Therapeutic Radiology and Oncology. 1987.
  100. Clark JR. Strategies in the multidisciplinary treatment of head and neck cancer. Presented at the symposium, Advances in Cancer Chemotherapy. 4th European Conference on Clinical Oncology, Madrid, Spain. 1987.
  101. Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr., Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. 1987; 60:2869-2872.
  102. Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr, Miller D. Cisplatin, adriamycin and cyclophosphamide (CAP) combination chemotherapy for salivary gland carcinomas. Presented at the Second International Conference on Head and Neck Cancer. 1987.
  103. Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG, Miller D, Fabian RL, Posner MR, Norris CM, Tuttle SA, Schoenfeld DA, et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987 Jan; 5(1):10-20. PMID: 2433406.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  104. Fallon BG, Clark J, Norris C Jr, Balogh K, Domanowski G, Andersen J, Dreyfuss A, Anderson R, Chaffey J, Miller D. Induction chemotherapy (CT) in advanced stage III/IV squamous cell carcinoma of the head and neck (SCCHN): An analysis of histopathology (HP) and failure (FAIL) in patients (pts) with a clinical complete response (CCR) in the primary site or neck. Presented at the Second International Conference on Head and Neck Cancer. 1987.
  105. Clark JR, Fallon BG, Frei E III. Induction chemotherapy as initial treatment for advanced head and neck cancer: A model for the multidisciplinary management of solid tumors. DeVita VT Jr, Hellman SA and Rosenberg SA. 1987; 175-195.
  106. Clark JR, Norris CM Jr, Dreyfuss AI, Fallon BG, Balogh K, Anderson RF Jr., Chaffey JT, Andersen JW, Miller D. Nasopharyngeal carcinoma: The Dana-Farber Cancer Institute experience with 24 patients treated with induction chemotherapy and radiotherapy. Annuals of Otology, Rhin and Laryngol. 1987; 96(5):608-614.
  107. Educational film with monograph. Outpatient Antifungal Therapy in Immunocompromised Hosts, Part of the Critical Decisions in Medicine Series. 1987.
  108. Clark JR. Induction chemotherapy for advanced head and neck cancer. Advances in Oncology. 1987; 3(1):23-29.
  109. Clark JR, Dreyfuss A, Fallon B, Norris C Jr, Balogh K, Anderson R, Chaffey J, Andersen J, Miller D. Nasopharyngeal carcinoma: The impact of T-stage, N-stage and histologic differentiation on response to chemotherapy and survival in 24 patients treated with induction chemotherapy and radiotherapy. Presented at the Second International Conference on Head and Neck Cancer. 1987.
  110. Posner MR, Skarin AT, Clark J, Ervin TJ. Phase I study of continuous-infusion cisplatin. Cancer Treat Rep. 1986 Jul; 70(7):847-50. PMID: 3013401.
    Citations: 4     Fields:    Translation:Humans
  111. Frei E, Clark JR, Fallon BG. Guidelines, regulations, and clinical research. J Clin Oncol. 1986 Jul; 4(7):1026-30. PMID: 3723164.
    Citations:    Fields:    Translation:Humans
  112. Norris CM, Clark JR, Frei E, Ervin TJ, Fallon B, Tuttle SA, Fabian RL, Miller D. Pathology of surgery after induction chemotherapy: an analysis of resectability and locoregional control. Laryngoscope. 1986 Mar; 96(3):292-302. PMID: 3951307.
    Citations: 1     Fields:    Translation:Humans
  113. Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J, Ervin TJ. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head and neck cancer patients. Proc Natl Acad Sci. 1986; 83:2684-2688.
  114. Clark J, Fallon B, Norris C, Miller D, Fabian R, Weichselbaum R, Anderson R, Chaffey J, Ervin T, Frei E. A randomized trial of two induction regimens for advanced squamous cell carcinoma of the head and neck (SCCHN) - Preliminary results. ASCO Meetings, May 4-6. 1986.
  115. Educational film with monograph. the Superior Vena Caval Syndrome, Part of the Critical Decisions in Medicine Series. 1986.
  116. Archibald D, Lockhart PB, Sonis ST, Ervin TJ, Fallon BG, Miller D, Clark JR. Oral complications of multimodality therapy for advanced squamous cell carcinoma of the head and neck. Oral Surg, Oral Med, Oral Path. 1986; 61(2):139-141.
  117. Fallon BG, Clark JR, Frei E. Vascular complications during cisplatin-bleomycin-methotrexate and cisplatin-5-FU induction chemotherapy for advanced stage III and IV squamous cell carcinoma of the head and neck. ASCO Meetings, May 4-6. 1986.
  118. Groopman JE, Mayer K, Zipoli T, Wallach S, Fallon B, Clark J. Unusual neoplasms associated with HTLV-III infection. Proceedings of ASCO. 1986.
  119. Frei E, Miller D, Clark JR, Fallon BG, Ervin TJ. Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. Recent Results Cancer Res. 1986; 103:1-5. PMID: 3738192.
    Citations: 6     Fields:    Translation:Humans
  120. Ervin TJ, Clark JR, Weichselbaum RR. Multidisciplinary treatment of advanced squamous carcinoma of the head and neck. Semin Oncol. 1985 Dec; 12(4 Suppl 6):71-8. PMID: 3909421.
    Citations: 1     Fields:    Translation:Humans
  121. Posner MR, Weichselbaum RR, Fitzgerald TJ, Clark JR, Rose C, Fabian RL, Norris CM, Miller D, Tuttle SA, Ervin TJ. Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1985 Nov; 11(11):1887-93. PMID: 2414254.
    Citations: 3     Fields:    Translation:Humans
  122. Loeffler JS, Larson DA, Clark JR, Weichselbaum RR, Norris CM, Ervin TJ. Treatment of perineural metastasis from squamous carcinoma of the skin with aggressive combination chemotherapy and irradiation. J Surg Oncol. 1985 Jul; 29(3):181-3. PMID: 4079398.
    Citations: 5     Fields:    Translation:Humans
  123. Ervin TJ, Weichselbaum RR, Clark JR, Boeheim K. Rationale for combination chemotherapy as treatment of advanced head and neck cancer. Head and Neck Cancer. 1985; 1:427-428.
  124. Fallon BG, Clark JC, Weichselbaum RR, Miller D, Norris CM, Jr, Fabian R, Frei E, Ervin TJ. Locoregional control in advanced squamous cell carcinoma of the head and neck (SCCHN) after induction chemotherapy. ASCO Meetings, May 19-21. 1985.
  125. Norris CM Jr, Clark JR, Fallon B, Fabian RL, Ervin TJ, Tuttle SA, Frei E III, Miller D. The pathology of surgery after induction chemotherapy. American Society for Head and Neck Surgery and the Society of Head and Neck Surgeons, May 5-8. 1985.
  126. Ervin TJ, Clark JR, Weichselbaum RR. Chemotherapy in the treatment of squamous cell carcinoma of the head and neck. Current Concepts in Oncology. 1985; 7(10).
  127. Weichselbaum RR, Clark JR, Miller D, Posner MR, Ervin TJ. Combined modality treatment of head and neck cancer with cis-platinum, bleomycin, methotrexate-leucovorin chemotherapy. 1985; 51:2149-2155.
  128. Govil RM, Clark JR, O'Connor T, Wagner H, Ervin TJ. Combination chemotherapy for skin carcinoma. ASCO Meetings, May 19-21. 1985.
  129. Clark JR, Fallon BG, Weichselbaum RR, Miller D, Fabian R, Norris CM Jr, Frei E, Ervin TJ. The influence of resectability on response to induction chemotherapy and survival in advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meetings, May 19-21. 1985.
  130. Strong MS, Wang CC, Clark JC. Cancer of the head and neck. Cancer manual, 7th Edition, Cady B. 1985; 132-140.
  131. Weichselbaum RR, Clark JR, Miller D, Posner MR, Chaffey JT, Fabian R, Norris C, Fitzgerald TJ, Rose C, Ervin TJ. Combination treatment of head and neck cancer with induction chemotherapy. Head and Neck Cancer Vol 1. 1985.
  132. Weichselbaum RR, Fitzgerald TJ, Posner M, Miller D, Fabian R Norris C, Clark J, Ervin TJ Chaffey JT. Toxicity of chemotherapy and radiotherapy in the treatment of locally advanced cancer of the head and neck. Int J Rad Oncol Biol Phys. 1984; 10-100.
  133. Weichselbaum RR, Fitzgerald TJ, Posner M, Miller D, Fabian R, Norris C, Clark J, Ervin TJ, Chaffey JT. Toxicity of chemotherapy and radiotherapy in the treatment of locally advanced cancer of the head and neck. Int J Radiation Oncol Biol Phys. 1984; 10(2):45.
  134. Educational film with monograph. the Hypercalcemia of Malignancy, Part of the Critical Decisions in Medicine Series. 1982.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Clark's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (211)
Explore
_
Co-Authors (59)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.